使用对短期马拉维若单药治疗暴露的病毒学反应验证HIV嗜性检测TROCAI
Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
作者信息
Gonzalez-Serna A, Genebat M, De Luna-Romero M, Tarancon-Diez L, Dominguez-Molina B, Pacheco Y M, Muñoz-Fernández M A, Leal M, Ruiz-Mateos E
机构信息
Molecular Immunobiology Laboratory, General Universitary Hospital Gregorio Marañon, Health Research Institute Gregorio Marañon, Spanish HIV HGM BioBank, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain Laboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain
Laboratory of Immunovirology, Biomedicine Institute of Seville, Virgen del Rocío University Hospital, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, IBIS/CSIC/SAS/University of Seville, Seville, Spain.
出版信息
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401. doi: 10.1128/AAC.01326-16. Print 2016 Oct.
TROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.
TROCAI是一种表型嗜性检测方法，通过对短期使用马拉维若单药治疗（马拉维若临床试验[MCT]）的病毒学反应来开发。研究发现，使用TROCAI时，需要将双重/混合病毒的截断值设定为<0.5%才能预测R5型HIV嗜性。在此，我们使用该截断值在42例新患者队列中对TROCAI进行了验证，发现TROCAI与MCT之间具有非常高的一致性（98%），与其他基因型/表型方法也具有良好的一致性（71%至87%）。
Zotero 插件